Acta Med. 2021, 64: 132-135
https://doi.org/10.14712/18059694.2021.23
Failure of Warfarin Anticoagulation Therapy after Administration of Oral Terbinafine
References
1. S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke 2013; 44: 3103–8.
<https://doi.org/10.1161/STROKEAHA.113.002329>
2. RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857–67.
<https://doi.org/10.7326/0003-4819-146-12-200706190-00007>
3. H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2017; 38: 2137–49.
4. J, Mills-Bomford J, Williams T. Interaction between warfarin and oral terbinafine. Manufacturer does not agree that interaction was with terbinafine. BMJ 1998; 317(7152): 205; author reply 205.
<https://doi.org/10.1136/bmj.317.7152.205a>
<PubMed>
5. JA, Corrall RJ. Serious interaction between warfarin and oral terbinafine. BMJ 1998; 316: 440.
<https://doi.org/10.1136/bmj.316.7129.440>
<PubMed>
6. LS, Zhang Z-Y. Human P450 metabolisms of warfarin. Pharmacol Ther 1997; 73(1): 67–74.
<https://doi.org/10.1016/S0163-7258(96)00140-4>
7. K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38(2): 111–80.
<https://doi.org/10.2165/00003088-200038020-00002>
